Cardiac remodeling in systemic hypertension

Medical Clinics of North America

Volumn 88, Issue 1, 2004, Pages 115-130

  Kenchaiah, Satish ^a,b   Pfeffer, Marc A ^a,c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c PARTNERS HEALTHCARE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT;

BLOOD PRESSURE; CARDIOVASCULAR RISK; DIASTOLE; DISEASE COURSE; ELECTROCARDIOGRAM; HEART ATRIUM HYPERTROPHY; HEART FUNCTION; HEART LEFT ATRIUM; HEART MUSCLE FIBROSIS; HEART VENTRICLE HYPERTROPHY; HEMODYNAMICS; HUMAN; HYPERTENSION; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; REMISSION; REVIEW; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME;

EID: 0742304959     PISSN: 00257125     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0025-7125(03)00168-8     Document Type: Review

References (152)

1. Holt J.P., Rhode E.A., Kines H. Ventricular volumes and body weight in mammals. Am J Physiol. 215:1968;704-715.
2. Bright R. Tubular view of the morbid appearances in 100 cases connected with albimunious urine: with observations. Guys Hosp Rep. 1:1936;380-400.
3. Johnson S. On certain points in the anatomy and pathology of Bright's diseases of kidney, II; on the influence of the minute blood-vessels upon the circulation. Med Chir Trans. 51:1868;57-80.
4. Goldblatt H., Lynch R., Hanzal R.F., Summerville W.W. Studies on experimental hypertension I. The production of persistent elevation of systolic blood pressure by means of renal ischemia . J Exp Med. 59:1934;347-379.
5. Chanutin A., Barksdale E.E. Experimental renal insufficiency produced by partial nephrectomy. Arch Intern Med. 52:1933;731-751.
6. Tarazi R.C., Miller A., Frohlich E.D., Dustan H.P. Electrocardiographic changes reflecting left atrial abnormality in hypertension. Circulation. 34:1966;818-822.
7. Frohlich E.D., Tarazi R.C., Dustan H.P. Clinical-physiological correlations in the development of hypertensive heart disease. Circulation. 44:1971;446-455.
8. Dunn F.G., Chandraratna P., deCarvalho J.G., Basta L.L., Frohlich E.D. Pathophysiologic assessment of hypertensive heart disease with echocardiography. Am J Cardiol. 39:1977;789-795.
9. Pearson A.C., Gudipati C., Nagelhout D., Sear J., Cohen J.D., Labovitz A.J. Echocardiographic evaluation of cardiac structure and function in elderly subjects with isolated systolic hypertension. J Am Coll Cardiol. 17:1991;422-430.
10. Gerdts E., Oikarinen L., Palmieri V., Otterstad J.E., Wachtell K., Boman K., et al. Correlates of left atrial size in hypertensive patients with left ventricular hypertrophy: the Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) Study. Hypertension. 39:2002;739-743.
11. Tedesco M.A., Di Salvo G., Ratti G., Natale F., Iarussi D., Iacono A. Left atrial size in 164 hypertensive patients: an echocardiographic and ambulatory blood pressure study. Clin Cardiol. 24:2001;603-607.
12. Vaziri S.M., Larson M.G., Lauer M.S., Benjamin E.J., Levy D. Influence of blood pressure on left atrial size: the Framingham Heart Study. Hypertension. 25:1995;1155-1160.
13. Valdez R.S., Motta J.A., London E., Martin R.P., Haskell W.L., Farquhar J.W., et al. Evaluation of the echocardiogram as an epidemiologic tool in an asymptomatic population. Circulation. 60:1979;921-929.
14. Galderisi M., Petrocelli A., Fakher A., Izzo A., Alfieri A., de Divitiis O. Influence of nighttime blood pressure on left atrial size in uncomplicated arterial systemic hypertension. Am J Hypertens. 10:1997;836-842.
15. Kannel W.B., Wolf P.A., Benjamin E.J., Levy D. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol. 82:1998;2N-9N.
16. Miller J.T., O'Rourke R.A., Crawford M.H. Left atrial enlargement: an early sign of hypertensive heart disease. Am Heart J. 116:1988;1048-1051.
17. Benjamin E.J., D'Agostino R.B., Belanger A.J., Wolf P.A., Levy D. Left atrial size and the risk of stroke and death: the Framingham Heart Study. Circulation. 92:1995;835-841.
18. Psaty B.M., Manolio T.A., Kuller L.H., Kronmal R.A., Cushman M., Fried L.P., et al. Incidence of and risk factors for atrial fibrillation in older adults. Circulation. 96:1997;2455-2461.
19. Di Tullio M.R., Sacco R.L., Sciacca R.R., Homma S. Left atrial size and the risk of ischemic stroke in an ethnically mixed population. Stroke. 30:1999;2019-2024.
20. Ciaroni S., Cuenoud L., Bloch A. Clinical study to investigate the predictive parameters for the onset of atrial fibrillation in patients with essential hypertension. Am Heart J. 139:2000;814-819.
21. Tsang T.S., Barnes M.E., Bailey K.R., Leibson C.L., Montgomery S.C., Takemoto Y., et al. Left atrial volume: important risk marker of incident atrial fibrillation in 1655 older men and women. Mayo Clin Proc. 76:2001;467-475.
22. Appleton C.P., Galloway J.M., Gonzalez M.S., Gaballa M., Basnight M.A. Estimation of left ventricular filling pressures using two-dimensional and Doppler echocardiography in adult patients with cardiac disease: additional value of analyzing left atrial size, left atrial ejection fraction and the difference in duration of pulmonary venous and mitral flow velocity at atrial contraction. J Am Coll Cardiol. 22:1993;1972-1982.
23. Dreslinski G.R., Frohlich E.D., Dunn F.G., Messerli F.H., Suarez D.H., Reisin E. Echocardiographic diastolic ventricular abnormality in hypertensive heart disease: atrial emptying index. Am J Cardiol. 47:1981;1087-1090.
24. Inouye I., Massie B., Loge D., Topic N., Silverstein D., Simpson P., et al. Abnormal left ventricular filling: an early finding in mild to moderate systemic hypertension. Am J Cardiol. 53:1984;120-126.
25. Smith V.E., Schulman P., Karimeddini M.K., White W.B., Meeran M.K., Katz A.M. Rapid ventricular filling in left ventricular hypertrophy: II. Pathologic hypertrophy . J Am Coll Cardiol. 5:1985;869-874.
26. Matsuda M., Matsuda Y. Mechanism of left atrial enlargement related to ventricular diastolic impairment in hypertension. Clin Cardiol. 19:1996;954-959.
27. Franz I.W., Tonnesmann U., Muller J.F. Time course of complete normalization of left ventricular hypertrophy during long-term antihypertensive therapy with angiotensin converting enzyme inhibitors. Am J Hypertens. 11:(6 pt 1):1998;631-639.
28. Kannel W.B., Dannenberg A.L., Levy D. Population implications of electrocardiographic left ventricular hypertrophy. Am J Cardiol. 60:1987;85I-93I.
29. Frohlich E.D., Apstein C., Chobanian A.V., Devereux R.B., Dustan H.P., Dzau V., et al. The heart in hypertension. N Engl J Med. 327:1992;998-1008.
30. Lorell B.H., Carabello B.A. Left ventricular hypertrophy: pathogenesis, detection, and prognosis. Circulation. 102:2000;470-479.
31. Marriott H.J.L. Practical electrocardiography. 10th edition: 2001;Lippincott Williams & Wilkins, Baltimore.
32. Levy D., Labib S.B., Anderson K.M., Christiansen J.C., Kannel W.B., Castelli W.P. Determinants of sensitivity and specificity of electrocardiographic criteria for left ventricular hypertrophy. Circulation. 81:1990;815-820.
33. Devereux R.B. Is the electrocardiogram still useful for detection of left ventricular hypertrophy? Circulation. 81:1990;1144-1146.
34. Haider A.W., Larson M.G., Benjamin E.J., Levy D. Increased left ventricular mass and hypertrophy are associated with increased risk for sudden death. J Am Coll Cardiol. 32:1998;1454-1459.
35. Levy D. Left ventricular hypertrophy: epidemiological insights from the Framingham Heart Study. Drugs. 35:(suppl 5):1988;1-5.
36. Daniels S.D., Meyer R.A., Loggie J.M. Determinants of cardiac involvement in children and adolescents with essential hypertension. Circulation. 82:1990;1243-1248.
37. Devereux R.B., Pickering T.G., Harshfield G.A., Kleinert H.D., Denby L., Clark L., et al. Left ventricular hypertrophy in patients with hypertension: importance of blood pressure response to regularly recurring stress. Circulation. 68:1983;470-476.
38. Ren J.F., Hakki A.H., Kotler M.N., Iskandrian A.S. Exercise systolic blood pressure: a powerful determinant of increased left ventricular mass in patients with hypertension. J Am Coll Cardiol. 5:1985;1224-1231.
39. Schnall P.L., Pieper C., Schwartz J.E., Karasek R.A., Schlussel Y., Devereux R.B., et al. The relationship between 'job strain,' workplace diastolic blood pressure, and left ventricular mass index: results of a case-control study. JAMA. 263:1990;1929-1935.
40. Drayer J.I., Weber M.A., DeYoung J.L. BP as a determinant of cardiac left ventricular muscle mass. Arch Intern Med. 143:1983;90-92.
41. Kobrin I., Oigman W., Kumar A., Ventura H.O., Messerli F.H., Frohlich E.D., et al. Diurnal variation of blood pressure in elderly patients with essential hypertension. J Am Geriatr Soc. 32:1984;896-899.
42. Schunkert H., Hense H.W., Holmer S.R., Stender M., Perz S., Keil U., et al. Association between a deletion polymorphism of the angiotensin-converting- enzyme gene and left ventricular hypertrophy. N Engl J Med. 330:1994;1634-1638.
43. Bowman J.C., Steinberg S.F., Jiang T., Geenen D.L., Fishman G.I., Buttrick P.M. Expression of protein kinase C beta in the heart causes hypertrophy in adult mice and sudden death in neonates. J Clin Invest. 100:1997;2189-2195.
44. Hernandez D., Lacalzada J., Rufino M., Torres A., Martin N., Barragan A., et al. Prediction of left ventricular mass changes after renal transplantation by polymorphism of the angiotensin-converting-enzyme gene. Kidney Int. 51:1997;1205-1211.
45. Brull D., Dhamrait S., Myerson S., Erdmann J., Woods D., World M., et al. Bradykinin B2BKR receptor polymorphism and left-ventricular growth response. Lancet. 358:2001;1155-1156.
46. Anversa P., Ricci R., Olivetti G. Quantitative structural analysis of the myocardium during physiologic growth and induced cardiac hypertrophy: a review. J Am Coll Cardiol. 7:1986;1140-1149.
47. Jalil J.E., Doering C.W., Janicki J.S., Pick R., Shroff S.G., Weber K.T. Fibrillar collagen and myocardial stiffness in the intact hypertrophied rat left ventricle. Circ Res. 64:1989;1041-1050.
48. Hamet P., Richard L., Dam T.V., Teiger E., Orlov S.N., Gaboury L., et al. Apoptosis in target organs of hypertension. Hypertension. 26:1995;642-648.
49. Masaki T., Kimura S., Yanagisawa M., Goto K. Molecular and cellular mechanism of endothelin regulation: implications for vascular function. Circulation. 84:1991;1457-1468.
50. Dzau V.J. Tissue renin-angiotensin system in myocardial hypertrophy and failure. Arch Intern Med. 153:1993;937-942.
51. Sadoshima J., Xu Y., Slayter H.S., Izumo S. Autocrine release of angiotensin II mediates stretch-induced hypertrophy of cardiac myocytes in vitro. Cell. 75:1993;977-984.
52. Rapacciuolo A., Esposito G., Caron K., Mao L., Thomas S.A., Rockman H.A. Important role of endogenous norepinephrine and epinephrine in the development of in vivo pressure-overload cardiac hypertrophy. J Am Coll Cardiol. 38:2001;876-882.
53. Mahoney L.T., Schieken R.M., Clarke W.R., Lauer R.M. Left ventricular mass and exercise responses predict future blood pressure: the Muscatine Study. Hypertension. 12:1988;206-213.
54. de Simone G., Devereux R.B., Roman M.J., Schlussel Y., Alderman M.H., Laragh J.H. Echocardiographic left ventricular mass and electrolyte intake predict arterial hypertension. Ann Intern Med. 114:1991;202-209.
55. Iso H., Kiyama M., Doi M., Nakanishi N., Kitamura A., Naito Y., et al. Left ventricular mass and subsequent blood pressure changes among middle-aged men in rural and urban Japanese populations. Circulation. 89:1994;1717-1724.
56. Post W.S., Larson M.G., Levy D. Impact of left ventricular structure on the incidence of hypertension: the Framingham Heart Study. Circulation. 90:1994;179-185.
57. Greenwood J.P., Scott E.M., Stoker J.B., Mary D.A. Hypertensive left ventricular hypertrophy: relation to peripheral sympathetic drive. J Am Coll Cardiol. 38:2001;1711-1717.
58. Shear C.L., Webber L.S., Freedman D.S., Srinivasan S.R., Berenson G.S. The relationship between parental history of vascular disease and cardiovascular disease risk factors in children: the Bogalusa Heart Study. Am J Epidemiol. 122:1985;762-771.
59. Adams T.D., Yanowitz F.G., Fisher A.G., Ridges J.D., Nelson A.G., Hagan A.D., et al. Heritability of cardiac size: an echocardiographic and electrocardiographic study of monozygotic and dizygotic twins. Circulation. 71:1985;39-44.
60. Nielsen J.R., Oxhoj H. Echocardiographic variables in progeny of hypertensive and normotensive parents. Acta Med Scand Suppl. 693:1985;61-64.
61. Radice M., Alli C., Avanzini F., Di Tullio M., Mariotti G., Taioli E., et al. Left ventricular structure and function in normotensive adolescents with a genetic predisposition to hypertension. Am Heart J. 111:1986;115-120.
62. Fagard R., Van Den B.C., Bielen E., Amery A. Maximum oxygen uptake and cardiac size and function in twins. Am J Cardiol. 60:1987;1362-1367.
63. Harshfield G.A., Grim C.E., Hwang C., Savage D.D., Anderson S.J. Genetic and environmental influences on echocardiographically determined left ventricular mass in black twins. Am J Hypertens. 3:1990;538-543.
64. Verhaaren H.A., Schieken R.M., Mosteller M., Hewitt J.K., Eaves L.J., Nance W.E. Bivariate genetic analysis of left ventricular mass and weight in pubertal twins (the Medical College of Virginia twin study). Am J Cardiol. 68:1991;661-668.
65. Kannel W.B., Gordon T., Castelli W.P., Margolis J.R. Electrocardiographic left ventricular hypertrophy and risk of coronary heart disease: the Framingham study. Ann Intern Med. 72:1970;813-822.
66. Kannel W.B., Castelli W.P., McNamara P.M., McKee P.A., Feinleib M. Role of blood pressure in the development of congestive heart failure: the Framingham study. N Engl J Med. 287:1972;781-787.
67. Kannel W.B., Levy D., Cupples L.A. Left ventricular hypertrophy and risk of cardiac failure: insights from the Framingham Study. J Cardiovasc Pharmacol. 10:(suppl 6):1987;S135-S140.
68. Messerli F.H., Ventura H.O., Elizardi D.J., Dunn F.G., Frohlich E.D. Hypertension and sudden death: increased ventricular ectopic activity in left ventricular hypertrophy. Am J Med. 77:1984;18-22.
69. Aronow W.S., Epstein S., Schwartz K.S., Koenigsberg M. Correlation of complex ventricular arrhythmias detected by ambulatory electrocardiographic monitoring with echocardiographic left ventricular hypertrophy in persons older than 62 years in a long-term health care facility. Am J Cardiol. 60:1987;730-732.
70. Levy D., Anderson K.M., Savage D.D., Balkus S.A., Kannel W.B., Castelli W.P. Risk of ventricular arrhythmias in left ventricular hypertrophy: the Framingham Heart Study. Am J Cardiol. 60:1987;560-565.
71. McLenachan J.M., Henderson E., Morris K.I., Dargie H.J. Ventricular arrhythmias in patients with hypertensive left ventricular hypertrophy. N Engl J Med. 317:1987;787-792.
72. Siegel D., Cheitlin M.D., Black D.M., Seeley D., Hearst N., Hulley S.B. Risk of ventricular arrhythmias in hypertensive men with left ventricular hypertrophy. Am J Cardiol. 65:1990;742-747.
73. Chiang B.N., Perlman L.V., Fulton M., Ostrander L.D. Jr., Epstein F.H. Predisposing factors in sudden cardiac death in Tecumseh, Michigan. A prospective study. Circulation. 41:1970;31-37.
74. Kannel W.B., Schatzkin A. Sudden death: lessons from subsets in population studies. J Am Coll Cardiol. 5:(6 suppl):1985;141B-149B.
75. Kannel W.B., Dannenberg A.L., Levy D. Population implications of electrocardiographic left ventricular hypertrophy. Am J Cardiol. 60:1987;85I-93I.
76. Verdecchia P., Porcellati C., Reboldi G., Gattobigio R., Borgioni C., Pearson T.A., et al. Left ventricular hypertrophy as an independent predictor of acute cerebrovascular events in essential hypertension. Circulation. 104:2001;2039-2044.
77. Dunn F.G., Pringle S.D. Sudden cardiac death, ventricular arrhythmias and hypertensive left ventricular hypertrophy. J Hypertens. 11:1993;1003-1010.
78. Levy D., Garrison R.J., Savage D.D., Kannel W.B., Castelli W.P. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med. 322:1990;1561-1566.
79. Levy D., Garrison R.J., Savage D.D., Kannel W.B., Castelli W.P. Left ventricular mass and incidence of coronary heart disease in an elderly cohort: the Framingham Heart Study. Ann Intern Med. 110:1989;101-107.
80. Casale P.N., Devereux R.B., Milner M., Zullo G., Harshfield G.A., Pickering T.G., et al. Value of echocardiographic measurement of left ventricular mass in predicting cardiovascular morbid events in hypertensive men. Ann Intern Med. 105:1986;173-178.
81. Koren M.J., Devereux R.B., Casale P.N., Savage D.D., Laragh J.H. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med. 114:1991;345-352.
82. Levy D., Anderson K.M., Savage D.D., Balkus S.A., Kannel W.B., Castelli W.P. Risk of ventricular arrhythmias in left ventricular hypertrophy: the Framingham Heart Study. Am J Cardiol. 60:1987;560-565.
83. Ghali J.K., Kadakia S., Cooper R.S., Liao Y.L. Impact of left ventricular hypertrophy on ventricular arrhythmias in the absence of coronary artery disease. J Am Coll Cardiol. 17:1991;1277-1282.
84. Schmieder R.E., Messerli F.H. Determinants of ventricular ectopy in hypertensive cardiac hypertrophy. Am Heart J. 123:1992;89-95.
85. Novo S., Barbagallo M., Abrignani M.G., Nardi E., Di Maria G.U., Longo B., et al. Increased prevalence of cardiac arrhythmias and transient episodes of myocardial ischemia in hypertensives with left ventricular hypertrophy but without clinical history of coronary heart disease. Am J Hypertens. 10:1997;843-851.
86. Bikkina M., Levy D., Evans J.C., Larson M.G., Benjamin E.J., Wolf P.A., et al. Left ventricular mass and risk of stroke in an elderly cohort: the Framingham Heart Study. JAMA. 272:1994;33-36.
87. Haider A.W., Larson M.G., Benjamin E.J., Levy D. Increased left ventricular mass and hypertrophy are associated with increased risk for sudden death. J Am Coll Cardiol. 32:1998;1454-1459.
88. Liao Y., Cooper R.S., McGee D.L., Mensah G.A., Ghali J.K. The relative effects of left ventricular hypertrophy, coronary artery disease, and ventricular dysfunction on survival among black adults. JAMA. 273:1995;1592-1597.
89. Levy D., Anderson K.M., Savage D.D., Balkus S.A., Kannel W.B., Castelli W.P. Risk of ventricular arrhythmias in left ventricular hypertrophy: the Framingham Heart Study. Am J Cardiol. 60:1987;560-565.
90. Fragola P.V., Colivicchi F., Fabrizi E., Borzi M., Cannata D. Assessment of left ventricular hypertrophy in patients with essential hypertension: a rational basis for the electrocardiogram. Am J Hypertens. 6:1993;164-169.
91. Marcus M.L., Harrison D.G., Chilian W.M., Koyanagi S., Inou T., Tomanek R.J., et al. Alterations in the coronary circulation in hypertrophied ventricles. Circulation. 75:(1 pt 2):1987;I19-I25.
92. Dellsperger K.C., Marcus M.L. Effects of left ventricular hypertrophy on the coronary circulation. Am J Cardiol. 65:1990;1504-1510.
93. Polese A., De Cesare N., Montorsi P., Fabbiocchi F., Guazzi M., Loaldi A., et al. Upward shift of the lower range of coronary flow autoregulation in hypertensive patients with hypertrophy of the left ventricle. Circulation. 83:1991;845-853.
94. Beache G.M., Herzka D.A., Boxerman J.L., Post W.S., Gupta S.N., Faranesh A.Z., et al. Attenuated myocardial vasodilator response in patients with hypertensive hypertrophy revealed by oxygenation-dependent magnetic resonance imaging. Circulation. 104:2001;1214-1217.
95. Keung E.C., Aronson R.S. Non-uniform electrophysiological properties and electrotonic interaction in hypertrophied rat myocardium. Circ Res. 49:1981;150-158.
96. Hansen D.E., Craig C.S., Hondeghem L.M. Stretch-induced arrhythmias in the isolated canine ventricle: evidence for the importance of mechanoelectrical feedback. Circulation. 81:1990;1094-1105.
97. Stacy G.P. Jr., Jobe R.L., Taylor L.K., Hansen D.E. Stretch-induced depolarizations as a trigger of arrhythmias in isolated canine left ventricles. Am J Physiol. 263:(2 pt 2):1992;H613-H621.
98. Hart G. Cellular electrophysiology in cardiac hypertrophy and failure. Cardiovasc Res. 28:1994;933-946.
99. Volders P.G., Sipido K.R., Vos M.A., Kulcsar A., Verduyn S.C., Wellens H.J. Cellular basis of biventricular hypertrophy and arrhythmogenesis in dogs with chronic complete atrioventricular block and acquired torsades de pointes. Circulation. 98:1998;1136-1147.
100. Vos M.A., De Groot S.H., Verduyn S.C., van der Z.J., Leunissen H.D., Cleutjens J.P., et al. Enhanced susceptibility for acquired torsades de pointes arrhythmias in the dog with chronic, complete AV block is related to cardiac hypertrophy and electrical remodeling. Circulation. 98:1998;1125-1135.
101. van Hoeven K.H., Factor S.M. A comparison of the pathological spectrum of hypertensive, diabetic, and hypertensive-diabetic heart disease. Circulation. 82:1990;848-855.
102. Pfeffer J.M. Regression of left ventricular hypertrophy as viewed from the periphery. Curr Opin Cardiol. 9:1994;527-533.
103. Sen S., Tarazi R.C., Khairallah P.A., Bumpus F.M. Cardiac hypertrophy in spontaneously hypertensive rats. Circ Res. 35:1974;775-781.
104. Fenje P., Leenen F.H. Effects of minoxidil on blood pressure and cardiac hypertrophy in two-kidney, one-clip hypertensive rats. Can J Physiol Pharmacol. 63:1985;161-164.
105. MacMahon S.W., Wilcken D.E., Macdonald G.J. The effect of weight reduction on left ventricular mass: a randomized controlled trial in young, overweight hypertensive patients. N Engl J Med. 314:1986;334-339.
106. Jula A.M., Karanko H.M. Effects on left ventricular hypertrophy of long-term nonpharmacological treatment with sodium restriction in mild-to-moderate essential hypertension. Circulation. 89:1994;1023-1031.
107. Schmieder R.E., Martus P., Klingbeil A. Reversal of left ventricular hypertrophy in essential hypertension: meta-analysis of randomized double-blind studies. JAMA. 275:1996;1507-1513.
108. Hinderliter A., Sherwood A., Gullette E.C., Babyak M., Waugh R., Georgiades A., et al. Reduction of left ventricular hypertrophy after exercise and weight loss in overweight patients with mild hypertension. Arch Intern Med. 162:2002;1333-1339.
109. Liebson P.R., Grandits G.A., Dianzumba S., Prineas R.J., Grimm R.H. Jr., Neaton J.D., et al. Comparison of five antihypertensive monotherapies and placebo for change in left ventricular mass in patients receiving nutritional-hygienic therapy in the Treatment of Mild Hypertension Study (TOMHS). Circulation. 91:1995;698-706.
110. Gottdiener J.S., Reda D.J., Massie B.M., Materson B.J., Williams D.W., Anderson R.J. Effect of single-drug therapy on reduction of left ventricular mass in mild to moderate hypertension: comparison of six antihypertensive agents: the Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. Circulation. 95:1997;2007-2014.
111. Devereux R.B., Palmieri V., Liu J.E., Wachtell K., Bella J.N., Boman K., et al. Progressive hypertrophy regression with sustained pressure reduction in hypertension: the Losartan Intervention For Endpoint Reduction study. J Hypertens. 20:2002;1445-1450.
112. Wachtell K., Bella J.N., Rokkedal J., Palmieri V., Papademetriou V., Dahlof B., et al. Change in diastolic left ventricular filling after one year of antihypertensive treatment: the Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) Study. Circulation. 105:2002;1071-1076.
113. Dahlof B., Devereux R.B., Kjeldsen S.E., Julius S., Beevers G., Faire U., et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 359:2002;995-1003.
114. Julien J., Dufloux M.A., Prasquier R., Chatellier G., Menard D., Plouin P.F., et al. Effects of captopril and minoxidil on left ventricular hypertrophy in resistant hypertensive patients: a 6 month double-blind comparison. J Am Coll Cardiol. 16:1990;137-142.
115. Leenen F.H., Holliwell D.L. Antihypertensive effect of felodipine associated with persistent sympathetic activation and minimal regression of left ventricular hypertrophy. Am J Cardiol. 69:1992;639-645.
116. Devereux R.B., Palmieri V., Sharpe N., De Quattro V., Bella J.N., de Simone G., et al. Effects of once-daily angiotensin-converting enzyme inhibition and calcium channel blockade-based antihypertensive treatment regimens on left ventricular hypertrophy and diastolic filling in hypertension: the prospective randomized enalapril study evaluating regression of ventricular enlargement (preserve) trial. Circulation. 104:2001;1248-1254.
117. Wachtell K., Palmieri V., Olsen M.H., Gerdts E., Papademetriou V., Nieminen M.S., et al. Change in systolic left ventricular performance after 3 years of antihypertensive treatment: the Losartan Intervention for Endpoint (LIFE) Study. Circulation. 106:2002;227-232.
118. Rials S.J., Wu Y., Xu X., Filart R.A., Marinchak R.A., Kowey P.R. Regression of left ventricular hypertrophy with captopril restores normal ventricular action potential duration, dispersion of refractoriness, and vulnerability to inducible ventricular fibrillation. Circulation. 96:1997;1330-1336.
119. Balogun M.O., Dunn F.G. Systolic and diastolic function following regression of left ventricular hypertrophy in hypertension. J Hypertens Suppl. 9:1991;S51-S55.
120. Levy D., Salomon M., D'Agostino R.B., Belanger A.J., Kannel W.B. Prognostic implications of baseline electrocardiographic features and their serial changes in subjects with left ventricular hypertrophy. Circulation. 90:1994;1786-1793.
121. Verdecchia P., Schillaci G., Borgioni C., Ciucci A., Gattobigio R., Zampi I., et al. Prognostic significance of serial changes in left ventricular mass in essential hypertension. Circulation. 97:1998;48-54.
122. Mathew J., Sleight P., Lonn E., Johnstone D., Pogue J., Yi Q., et al. Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril. Circulation. 104:2001;1615-1621.
123. Zak R. Cell proliferation during cardiac growth. Am J Cardiol. 31:1973;211-219.
124. Pfeffer J.M., Pfeffer M.A., Fishbein M.C., Frohlich E.D. Cardiac function and morphology with aging in the spontaneously hypertensive rat. Am J Physiol. 237:1979;H461-H468.
125. Thiedemann K.U., Holubarsch C., Medugorac I., Jacob R. Connective tissue content and myocardial stiffness in pressure overload hypertrophy: a combined study of morphologic, morphometric, biochemical, and mechanical parameters. Basic Res Cardiol. 78:1983;140-155.
126. Brilla C.G., Pick R., Tan L.B., Janicki J.S., Weber K.T. Remodeling of the rat right and left ventricles in experimental hypertension. Circ Res. 67:1990;1355-1364.
127. Conrad C.H., Brooks W.W., Hayes J.A., Sen S., Robinson K.G., Bing O.H. Myocardial fibrosis and stiffness with hypertrophy and heart failure in the spontaneously hypertensive rat. Circulation. 91:1995;161-170.
128. Anderson K.R., Sutton M.G., Lie J.T. Histopathological types of cardiac fibrosis in myocardial disease. J Pathol. 128:1979;79-85.
129. Pearlman E.S., Weber K.T., Janicki J.S., Pietra G.G., Fishman A.P. Muscle fiber orientation and connective tissue content in the hypertrophied human heart. Lab Invest. 46:1982;158-164.
130. Tanaka M., Fujiwara H., Onodera T., Wu D.J., Matsuda M., Hamashima Y., et al. Quantitative analysis of narrowings of intramyocardial small arteries in normal hearts, hypertensive hearts, and hearts with hypertrophic cardiomyopathy. Circulation. 75:1987;1130-1139.
131. Huysman J.A., Vliegen H.W., Van der L.A., Eulderink F. Changes in nonmyocyte tissue composition associated with pressure overload of hypertrophic human hearts. Pathol Res Pract. 184:1989;577-581.
132. Brilla C.G., Janicki J.S., Weber K.T. Impaired diastolic function and coronary reserve in genetic hypertension: role of interstitial fibrosis and medial thickening of intramyocardial coronary arteries. Circ Res. 69:1991;107-115.
133. Brilla C.G., Pick R., Tan L.B., Janicki J.S., Weber K.T. Remodeling of the rat right and left ventricles in experimental hypertension. Circ Res. 67:1990;1355-1364.
134. Eghbali M., Weber K.T. Collagen and the myocardium: fibrillar structure, biosynthesis and degradation in relation to hypertrophy and its regression. Mol Cell Biochem. 96:1990;1-14.
135. Weber K.T., Brilla C.G. Pathological hypertrophy and cardiac interstitium: fibrosis and renin-angiotensin-aldosterone system. Circulation. 83:1991;1849-1865.
136. Brilla C.G., Janicki J.S., Weber K.T. Cardioreparative effects of lisinopril in rats with genetic hypertension and left ventricular hypertrophy. Circulation. 83:1991;1771-1779.
137. Pahor M., Bernabei R., Sgadari A., Gambassi G. Jr., Lo G.P., Pacifici L., et al. Enalapril prevents cardiac fibrosis and arrhythmias in hypertensive rats. Hypertension. 18:1991;148-157.
138. Chevalier B., Heudes D., Heymes C., Basset A., Dakhli T., Bansard Y., et al. Trandolapril decreases prevalence of ventricular ectopic activity in middle-aged SHR. Circulation. 92:1995;1947-1953.
139. Brooks W.W., Bing O.H., Robinson K.G., Slawsky M.T., Chaletsky D.M., Conrad C.H. Effect of angiotensin-converting enzyme inhibition on myocardial fibrosis and function in hypertrophied and failing myocardium from the spontaneously hypertensive rat. Circulation. 96:1997;4002-4010.
140. Brilla C.G. Regression of myocardial fibrosis in hypertensive heart disease: diverse effects of various antihypertensive drugs. Cardiovasc Res. 46:2000;324-331.
141. Kojima M., Shiojima I., Yamazaki T., Komuro I., Zou Z., Wang Y., et al. Angiotensin II receptor antagonist TCV-116 induces regression of hypertensive left ventricular hypertrophy in vivo and inhibits the intracellular signaling pathway of stretch-mediated cardiomyocyte hypertrophy in vitro. Circulation. 89:1994;2204-2211.
142. Varo N., Etayo J.C., Zalba G., Beaumont J., Iraburu M.J., Montiel C., et al. Losartan inhibits the post-transcriptional synthesis of collagen type I and reverses left ventricular fibrosis in spontaneously hypertensive rats. J Hypertens. 17:1999;107-114.
143. Amann K., Greber D., Gharehbaghi H., Wiest G., Lange B., Ganten U., et al. Effects of nifedipine and moxonidine on cardiac structure in spontaneously hypertensive rats: stereological studies on myocytes, capillaries, arteries, and cardiac interstitium. Am J Hypertens. 5:1992;76-83.
144. Campbell S.E., Turek Z., Rakusan K., Kazda S. Cardiac structural remodelling after treatment of spontaneously hypertensive rats with nifedipine or nisoldipine. Cardiovasc Res. 27:1993;1350-1358.
145. Suzuki M., Yamanaka K., Nabata H., Tachibana M. Long term effects of amlodipine on organ damage, stroke and life span in stroke prone spontaneously hypertensive rats. Eur J Pharmacol. 228:1993;269-274.
146. Brilla C.G., Matsubara L.S., Weber K.T. Anti-aldosterone treatment and the prevention of myocardial fibrosis in primary and secondary hyperaldosteronism. J Mol Cell Cardiol. 25:1993;563-575.
147. Sen S., Tarazi R.C., Bumpus F.M. Cardiac hypertrophy and antihypertensive therapy. Cardiovasc Res. 11:1977;427-433.
148. Sen S., Tarazi R.C., Bumpus F.M. Biochemical changes associated with development and reversal of cardiac hypertrophy in spontaneously hypertensive rats. Cardiovasc Res. 10:1976;254-261.
149. Sen S., Tarazi R.C., Bumpus F.M. Effect of converting enzyme inhibitor (SQ14,225) on myocardial hypertrophy in spontaneously hypertensive rats. Hypertension. 2:1980;169-176.
150. Grimm D., Kromer E.P., Bocker W., Bruckschlegel G., Holmer S.R., Riegger G.A., et al. Regulation of extracellular matrix proteins in pressure-overload cardiac hypertrophy: effects of angiotensin converting enzyme inhibition. J Hypertens. 16:1998;1345-1355.
151. Brilla C.G., Funck R.C., Rupp H. Lisinopril-mediated regression of myocardial fibrosis in patients with hypertensive heart disease. Circulation. 102:2000;1388-1393.
152. Diez J., Querejeta R., Lopez B., Gonzalez A., Larman M., Martinez Ubago J.L. Losartan-dependent regression of myocardial fibrosis is associated with reduction of left ventricular chamber stiffness in hypertensive patients. Circulation. 105:2002;2512-2517.